Virus:Article Title: COVID-19 vaccination in children: a public health priority
Article Snippet: .. For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years., , , , Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation., The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children. ..
Article Title: COVID-19 vaccination in children: a public health priority.
Article Snippet: .. Children and adolescents, as a special population, were generally excluded from the initial clinical trials and, therefore, the vaccination was introduced later in this group.24 For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years.23-27 Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation.23,24 The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children.27 Moreover, unfortunately, inequalities in the distribution of vaccines, vaccine hesitancy, misinformation, and political complexities, make vaccination coverage insufficient to contain the pandemic.21 Immunogenicity of vaccines against Covid-19 in the pediatric population Overall, evidence of good immunogenicity has been observed for vaccines against Covid-19 in children. ..
Vaccines:Article Title: COVID-19 vaccination in children: a public health priority
Article Snippet: .. For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years., , , , Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation., The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children. ..
Article Title: COVID-19 vaccination in children: a public health priority.
Article Snippet: .. Children and adolescents, as a special population, were generally excluded from the initial clinical trials and, therefore, the vaccination was introduced later in this group.24 For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years.23-27 Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation.23,24 The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children.27 Moreover, unfortunately, inequalities in the distribution of vaccines, vaccine hesitancy, misinformation, and political complexities, make vaccination coverage insufficient to contain the pandemic.21 Immunogenicity of vaccines against Covid-19 in the pediatric population Overall, evidence of good immunogenicity has been observed for vaccines against Covid-19 in children. ..
Transmission Assay:Article Title: COVID-19 vaccination in children: a public health priority
Article Snippet: .. For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years., , , , Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation., The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children. ..
Article Title: COVID-19 vaccination in children: a public health priority.
Article Snippet: .. Children and adolescents, as a special population, were generally excluded from the initial clinical trials and, therefore, the vaccination was introduced later in this group.24 For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years.23-27 Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation.23,24 The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children.27 Moreover, unfortunately, inequalities in the distribution of vaccines, vaccine hesitancy, misinformation, and political complexities, make vaccination coverage insufficient to contain the pandemic.21 Immunogenicity of vaccines against Covid-19 in the pediatric population Overall, evidence of good immunogenicity has been observed for vaccines against Covid-19 in children. ..
other:
Clinical Proteomics:
Article Title: COVID-19 vaccination in children: a public health priority.
Article Snippet: .. Children and adolescents, as a special population, were generally excluded from the initial clinical trials and, therefore, the vaccination was introduced later in this group.24 For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years.23-27 Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation.23,24 The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children.27 Moreover, unfortunately, inequalities in the distribution of vaccines, vaccine hesitancy, misinformation, and political complexities, make vaccination coverage insufficient to contain the pandemic.21 Immunogenicity of vaccines against Covid-19 in the pediatric population Overall, evidence of good immunogenicity has been observed for vaccines against Covid-19 in children. ..
Immunopeptidomics:Article Title: COVID-19 vaccination in children: a public health priority.
Article Snippet: .. Children and adolescents, as a special population, were generally excluded from the initial clinical trials and, therefore, the vaccination was introduced later in this group.24 For example, in Brazil, the inactivated virus vaccine by the pharmaceutical company Sinovac Biotech (CoronaVac) received conditional approval for the immunization of the pediatric population aged over three years, and the messenger RNA (mRNA) vaccine BNT162b2, developed in collaboration with Pfizer and BioNTech laboratories, was successively authorized for use in adolescents aged 12 to 18 years, later children aged five to 11 years with a special presentation containing one-third of the standard dose and which subsequently received authorization from the US regulatory agency Food and Drug Administration (FDA) and the Brazilian National Health Surveillance Agency (ANVISA) for another pediatric presentation, corresponding to one-tenth of the adult dose, for use in children aged 6 months to 4 years.23-27 Despite the crucial importance of vaccines in controlling the pandemic, there have been difficulties in efficient vaccine implementation.23,24 The introduction of effective vaccines against SARS-CoV-2, initially in school-aged children and adult populations, combined with the emergence of new variants of SARS-CoV-2, with greater transmission capacity, resulted in a proportional increase in infections in younger children.27 Moreover, unfortunately, inequalities in the distribution of vaccines, vaccine hesitancy, misinformation, and political complexities, make vaccination coverage insufficient to contain the pandemic.21 Immunogenicity of vaccines against Covid-19 in the pediatric population Overall, evidence of good immunogenicity has been observed for vaccines against Covid-19 in children. ..
|
